Sandy Srinivas
Clinical Trials
- Recruiting Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
- Recruiting Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery
- Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
- Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
- Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
- Recruiting Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
- Not Recruiting F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
- Not Recruiting A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
- Not Recruiting A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
- Recruiting A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
- Recruiting DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
- Not Recruiting A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
- Not Recruiting Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
- Not Recruiting A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer
- Recruiting Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
- Not Recruiting Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy
- Recruiting Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC
- Not Recruiting Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance
- Not Recruiting Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Not Recruiting Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Not Recruiting A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
- Not Recruiting Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
- Not Recruiting A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
- Not Recruiting A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
- Not Recruiting AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
- Not Recruiting Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
- Not Recruiting Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
- Not Recruiting MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
- Not Recruiting Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
- Not Recruiting First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
- Not Recruiting Phase 2 Trial of Enzastaurin in Prostate Cancer in Patients Who Have Had Hormonal and Chemotherapy
- Not Recruiting Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Not Recruiting BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
- Not Recruiting Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- Not Recruiting Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
- Not Recruiting Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
- Not Recruiting A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
- Not Recruiting TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
- Not Recruiting A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
- Not Recruiting Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1
- Not Recruiting A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
- Not Recruiting A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
- Not Recruiting A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
- Not Recruiting A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- Not Recruiting Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
- Not Recruiting Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
- Not Recruiting Fulvestrant in Hormone Refractory Prostate Cancer
- Not Recruiting Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation
- Not Recruiting Study of Itraconazole in Castration Resistant Prostate Cancer (CRPC) Post Docetaxel Chemotherapy
- Not Recruiting Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
- Recruiting Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
- Recruiting A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
- Recruiting Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
- Not Recruiting Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
- Not Recruiting Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Help